Alzheimer's disease
Neurology · 2007–2015
4decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rivastigmine Treatment of mild to moderately severe Alzheimer-type dementia. This submission seeks listing of an additional patch strength (13.3 mg/24 hours) to provide an… | Jul 2015 | Recommended | none received |
| memantine hydrochloride Treatment of moderately severe Alzheimer's disease in patients with baseline (Standardised) Mini-Mental State Examination ((S)MMSE) score of 10-14. | Mar 2008 | Recommended with restriction | no section in document |
| memantine hydrochloride treatment of moderately severe Alzheimer’s disease | Mar 2007 | Not recommended | no section in document |
| memantine hydrochloride Treatment of moderately severe Alzheimer's disease in patients with baseline Mini-Mental State Examination (MMSE) score of 10-14. | Mar 2007 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.